Willem A. Nolen

Willem A. Nolen

Auto-generated profile, based on publicly available information

Willem A. Nolen

Department of Psychiatry, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2008 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
PSP F Sullivan
P F Sullivan
EGEco De Geus
Eco De Geus
GWG Willemsen
G Willemsen
MJM R James
M R James
JSJ H Smit
J H Smit
BPB W J H Penninx
B W J H Penninx
Major depressive disorder (MDD) is a common complex trait with enormous public health significance. As part of the Genetic Association Information Network initiative of the US Foundation for the National Institutes of Health, we conducted a genome-wide association study of 435 291 single nucleotide polymorphisms (SNPs) genotyped in 1738 MDD cases and 1802 controls selected to be at low liability for MDD. Of the top 200, 11 signals localized to a 167 kb region overlapping the gene piccolo (PCLO, whose protein product localizes to the cytomatrix of the presynaptic active zone and is important in monoaminergic neurotransmission in the brain) with P-values of 7.7 × 10−7 for rs2715148 and 1.2 × 10−6 for rs2522833. We undertook replication of SNPs in this region in five independent samples (6079 MDD independent cases and 5893 controls) but no SNP exceeded the replication significance threshold when all replication samples were analyzed together. However, there was heterogeneity in the replication samples, and secondary analysis of the original sample with the sample of greatest similarity yielded P=6.4 × 10−8 for the nonsynonymous SNP rs2522833 that gives rise to a serine to alanine substitution near a C2 calcium-binding domain of the PCLO protein. With the integrated replication effort, we present a specific hypothesis for further studies.

15 July 2005 in Bipolar Disorders
Verified
Journal Article
Closed access
PDF file
MHManon Hj Hillegers
Manon Hj Hillegers
CRCatrien G Reichart
Catrien G Reichart
MWMarjolein Wals
Marjolein Wals
FVFrank C Verhulst
Frank C Verhulst
JOJohan Ormel
Johan Ormel
WNWillem A Nolen
Willem A Nolen

30 March 2010 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
YLY Liu
Y Liu
DBD H Blackwood
D H Blackwood
SCS Caesar
S Caesar
EGEco De Geus
Eco De Geus
AFA Farmer
A Farmer
WCWellcome Trust Case-Control Consortium
Wellcome Trust Case-Control Consortium

21 May 2019 in Bipolar Disorders
Verified
Journal Article
Open access
PDF file
WNWillem A. Nolen
Willem A. Nolen
RLRasmus W. Licht
Rasmus W. Licht
Allan YoungAllan Young
Allan Young
GMGin S. Malhi
Gin S. Malhi
MTMauricio Tohen
Mauricio Tohen
TLThe Isbd/Igsli Task Force On The Treatment With Lithium
The Isbd/Igsli Task Force On The Treatment With Lithium
Aims: To systematically review the existing trials on optimal serum levels for lithium for maintenance treatment of bipolar disorder and to develop clinical recommendations.Methods: Systematic literature search. Discussion of major characteristics, limitations, methodological quality, and results of selected trials. Delphi survey consisting of clinical questions and corresponding statements. For statements endorsed by at least 80% of the members, consensus was considered as having been achieved.Results: With strict inclusion criteria no studies could be selected, making it difficult to formulate evidence‐based recommendations. After loosening the inclusion criteria 7 trials were selected addressing our aims at least to some extent. Four of these studies suggest better efficacy being associated with lithium serum levels in a range above a lower threshold around 0.45/0.60 and up to 0.80/1.00 mmol/L. These findings support the outcome of the Delphi survey.Conclusions: For adults with bipolar disorder there was consensus that the standard lithium serum level should be 0.60‐0.80 mmol/L with the option to reduce it to 0.40‐0.60 mmol/L in case of good response but poor tolerance or to increase it to 0.80‐1.00 mmol/L in case of insufficient response and good tolerance. For children and adolescents there was no consensus, but the majority of the members endorsed the same recommendation. For the elderly there was also no consensus, but the majority of the members endorsed a more conservative approach: usually 0.40‐0.60 mmol/L, with the option to go to maximally 0.70 or 0.80 mmol/L at ages 65‐79 years, and to maximally 0.70 mmol/L over age 80 years.

1 February 2015 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
BHBartholomeus C.M. (Benno) Haarman
Bartholomeus C.M. (Benno) Haarman
RLRixt F. Riemersma-Van der Lek
Rixt F. Riemersma-Van der Lek
WNWillem A. Nolen
Willem A. Nolen
RMR. Mendes
R. Mendes
HDHemmo A. Drexhage
Hemmo A. Drexhage
Huibert BurgerHuibert Burger
Huibert Burger